Mega Lifesciences PCL (BKK:MEGA)

Market Cap	26.37B
Revenue (ttm)	14.86B
Net Income (ttm)	1.98B
Shares Out	871.87M
EPS (ttm)	2.28
PE Ratio	13.29
Forward PE	12.10
Dividend	1.60 (5.20%)
Ex-Dividend Date	Mar 7, 2025

Volume	1,305,265
Average Volume	1,122,719
Open	30.50
Previous Close	30.75
Day's Range	30.00 - 30.50
52-Week Range	24.30 - 41.25
Beta	0.27
RSI	65.58
Earnings Date	Aug 14, 2025

About CTI BioPharma

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1982
• Employees: 900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEGA

Financial Performance

In 2024, Mega Lifesciences PCL's revenue was 15.39 billion, a decrease of -2.10% compared to the previous year's 15.72 billion. Earnings were 2.01 billion, an increase of 0.99%.